WCLC 2023 | Recent developments in SCLC

Misty Shields, MD, PhD, Indiana University, Bloomington, IN, discusses recent strategies and novel therapies for small cell lung cancer (SCLC). Current studies demonstrate promise for second and third-line therapies, including bispecific T-cell engagers (BITEs) such as tarlatamab. Dr Shields also comments on new data on SCLC relapse in heavily pre-treated patients. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.